



## Genenta presents at ASGCT preliminary pre-clinical and clinical data from Temferon™ Phase 1/2 study in patients with glioblastoma multiforme

May 15, 2020

MILANO (Italy) / NEW YORK (NY, USA) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that they presented preliminary pre-clinical and clinical data from the TEM-GBM\_001 clinical trial at the international scientific meeting: American Society of Gene & Cell Therapy (ASGCT).

Dr Bernhard Gentner, Co-Founder of Genenta, presented relevant pre-clinical and clinical data from TEM-GBM\_001 study:

- Pre-clinical results support the rationale of taking Temferon™ to the clinic with the aim of breaking immune tolerance of tumors.
- Preliminary clinical results showed no dose-limiting toxicities, no systemic Interferon-alpha (IFN $\alpha$ ) side effects, successful Temferon™ engraftment and the follow-up analysis will evaluate the efficacy and biological activity.

### About Genenta Science

Genenta ([www.genenta.com](http://www.genenta.com)) has developed an ex-vivo gene transfer strategy into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Genenta's proprietary product is Temferon™.

The targeted expression of the immunomodulatory molecule in TEMs is achieved combining a transcriptional and post-transcriptional microRNA-mediated control. Thanks to these mechanisms, TEMs become capable of expressing the immunomodulatory molecule interferon-alpha (IFN- $\alpha$ ) in the tumor microenvironment.

TEMs are endowed with a pro-angiogenic activity and are spontaneously and actively recruited by developing tumors to sustain their growth. Thanks to the immune-gene transfer, TEMs become the tool for the local delivery of the immunomodulatory molecule. In preclinical models, the local IFN- $\alpha$  release triggered both a direct (anti-angiogenic, pro-apoptotic) and an indirect anti-tumor effect (immune response).

In contrast to antigen-restricted Chimeric Antigen Receptor T cells (CAR-T), Temferon™ is not restricted to pre-selected tumor antigens nor type and may reach not only hematologic disorders but more importantly, also solid tumors. In addition, its immunomodulatory functions may trigger a long-lasting immune response towards multiple tumor antigens.

As a result, Temferon™ should be able to break the tumor immune tolerance by reprogramming the tumor immune microenvironment.

Temferon is under investigation in two Phase I/II clinical trials in early relapse Multiple Myeloma patients after front line therapy and newly diagnosed Glioblastoma Multiforme patients.

Genenta's headquarter is in Milan (Italy) with an office in Alexandria Center's LaunchLabs, New York (NY, USA). The Company is part of Assobiotech, Italia StartUp, and ELITE (London Stock Exchange Group).

Co-founders: Pierluigi Paracchi, Ospedale San Raffaele (OSR), Prof. Luigi Naldini (Director SR-TIGET, San Raffaele Telethon Institute for Gene Therapy), and Dr. Bernhard Gentner (Hematologist and Physician-Scientist at OSR and SR-TIGET). Dr. Carlo Russo, MD serves as CMO & Head of Development. Genenta raised more than €30M in three different rounds of financing.

Genenta Media/Investor Contact:  
Valentina Brambilla, MSc  
+39 388 789.15.41  
[valentina.brambilla@genenta.com](mailto:valentina.brambilla@genenta.com)

**GENENTA SCIENCE Srl**  
Ospedale San Raffaele - DiBit 1 - Via Olgettina, 58 - 20132 Milan (Italy)  
LaunchLabs - Alexandria Center, 14th Floor –  
430 East 29th Street - New York, NY 10016 (USA)